Name: Recombinant Anti-PDGFR2 x Anti-VEGFR2 Bispecific Antibody (scFv-CH1/CL)
SKU: BSCC-187
Rating: 5 (1 reviews)

Recombinant Anti-PDGFR2 x Anti-VEGFR2 Bispecific Antibody (scFv-CH1/CL) is designed to be expressed as two chains. One scFv from an anti-PDGFR2 antibody variable domain is fused to CH1 and the other scFv from an anti-VEGFR2 antibody variable domain fused to CL, or vice versa. And the CH1 and CL domains are linked covalently via a natural disulfide bond. This BsAb can block two receptors simultaneously. It is designed for the research of Cancers therapy.

Datasheet INQUIRY

Specifications

Targets

PDGFR2 & VEGFR2

Type

scFv-CH1/CL

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Cancers

Host Animal 1

Mouse

Host Animal 2

Mouse

Targets

Target 1

PDGFR2

Gene ID

5156

UniProt ID

P16234

Alternative Names

PDGFRA; PDGFR2; platelet derived growth factor receptor, alpha polypeptide; CD140a; Pdgfr-2; AI115593; platelet-derived growth factor receptor alpha; PDGFR-alpha; PDGF-R-alpha; PDGF alpha chain; CD140 antigen-like family member A; platelet-derived growth factor alpha receptor; alpha-type platelet-derived growth factor receptor; Alpha platelet-derived growth factor receptor precursor (PDGF-R-alpha)

Target 2

VEGFR2

Gene ID

3791

UniProt ID

A0A024RD88

Alternative Names

FLK1; CD309; VEGFR; VEGFR2; Vascular endothelial growth factor receptor 2; Kinase insert domain receptor; Fetal liver kinase 1; Kinase insert domain receptor, a type III receptor; KDR

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-PDGFR2 x Anti-VEGFR2 Bispecific Antibody (scFv-CH1/CL) (BSCC-187). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-PDGFR2 x Anti-VEGFR2 Bispecific Antibody (scFv-CH1/CL) (CAT#: BSCC-187)

Specifications

Targets

Customer Reviews and Q&As